

**genzyme**  
**Legal Department**

*38*  
**OFFICIAL**

**Facsimile Message**

**TO:** USPTO, Group 1800, Art Unit 1814  
attention: Examiner Karen Carlson, Ph.D.  
(703) 305-7401

**RE:** 08/087,132 of Gregory et al. filed July 2, 1993

**FROM:** Elizabeth Lassen

**DATE:** April 15, 1996

**PAGES:** 17 (including cover)

**LEGAL DEPARTMENT**  
**Fax Number (508) 872-5415**

Enclosed herewith is a duplicate copy (with appropriate transmittals) of the supplementary amendment that was filed by facsimile on April 2, 1996. Thank you.

**FAX CENTER  
RECEIVED**

**APR 15 1996**

**GROUP 1800**

**Notice of Confidentiality**

This transmission is intended only for the addressee(s) listed above and may contain information that is confidential and privileged. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If you have received this transmission in error, please telephone us immediately and return the original message to us by mail. Thank you.

08/087.132

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory et. al.

Examiner: Dr. K. C. Carlson

Serial No.: 08/087,132

Art Unit: 1814

Filed: July 2, 1993

Docket: IG4-9.2 (FWC)

For: NEW DIAGNOSTIC AND TREATMENT METHODS INVOLVING THE  
CYSTIC FIBROSIS TRANSMEMBRANE REGULATORHonorable Assistant Commissioner  
of Patents  
Washington, DC 20231

## -- CERTIFICATE OF FACSIMILE TRANSMISSION --

I hereby certify that this correspondence is being  
transmitted by facsimile to the Honorable Assistant  
Commissioner of Patents, c/o Examiner Karen Carlson, Ph.D.,  
Group 1800, Art Unit 1814, Washington, DC 20231,  
at (703) 305-7401

Date: 4/2/96By: Elizabeth Lassen  
Elizabeth LassenSUPPLEMENTAL REPLY UNDER 37 CFR 1.111

S I R:

This Supplemental Reply is further to the Supplemental  
Reply with Amendment and the Supplemental Reply Under 37 CFR  
1.129 (a) and 37 CFR 1.116 that were submitted on January  
18, 1996 in response to the Final Rejection of December 22,  
1995.

The telephonic interview of January 31, 1996 conducted  
by Supervisory Patent Examiner Robert A. Wax and Examiner  
Karen Carlson, Ph.D. was greatly appreciated. By this